SEARCH RESULTS FOR:

Manoj Singhania

CEO, TRADEASIA INTERNATIONAL GROUP
"Digital platforms for industrial chemicals are becoming more and more important as the world embraces digital engagement in every sphere of our life."

Trevor P. Castor

PRESIDENT & CEO, APHIOS CORPORATION
"In 2021, we focused on introducing our green pathogen reduction technology to biotechnology and pharmaceutical companies."

Jeff Butler

PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."

Marcelo Awad

EXECUTIVE DIRECTOR, WEALTH MINERALS
"Just by developing known reserves, even without exploration success, Chile can increase its copper production by around 2 million t/y and its lithium production by around 1 million t/y."

Presas de Relaves: La Prevención de Fallas Catastróficas y los Principios ESG

MINPER 2022 - Perumin Official Investment Guide (Spanish Print Version)
Guillermo Barreda, General Manager, Knight Piésold Peru

APLA 2022 Registrations are Open

"Turn off your webcam, because this year we will meet again face to face."

Antonio Samaniego

DIRECTOR, SRK CONSULTING - PERÚ
SRK Consulting analyzes the current state of the Peruvian mining industry. (Spanish interview)

Louis Kassa

PRESIDENT & CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Our blueprint to success has manifested in six IPOs and over US$3 billion worth of company value created."

Jan Kengelbach

CEO, AENOVA GROUP
"While it's always easier to deny a certain service if you don't yet have the technical expertise in a particular area, in the long-term it is advantageous to explore the possibility of investing in that area with the customer."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS